{
    "ticker": "ANAB",
    "name": "AnaptysBio, Inc.",
    "description": "AnaptysBio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies for the treatment of severe diseases. Founded in 2005 and headquartered in San Diego, California, AnaptysBio utilizes its proprietary antibody discovery platform, which is designed to identify high-affinity antibodies with unique mechanisms of action. The company\u2019s pipeline includes innovative candidates targeting various therapeutic areas, including immunology and oncology. AnaptysBio's lead product candidate, etokimab, is an anti-IL-33 monoclonal antibody being developed for the treatment of atopic dermatitis and other inflammatory diseases. The company is also advancing several other programs, including antibodies targeting PD-1 and PD-L1 for cancer treatment. With a strong emphasis on scientific rigor and collaboration, AnaptysBio partners with leading pharmaceutical companies to leverage its technology and enhance its capabilities in antibody development. The company is committed to addressing unmet medical needs and improving patient outcomes through its pioneering approaches in biotherapeutics.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2005",
    "website": "https://www.anaptysbio.com",
    "ceo": "G. Thomas Adams",
    "social_media": {
        "twitter": "https://twitter.com/AnaptysBio",
        "linkedin": "https://www.linkedin.com/company/anaptysbio/"
    },
    "investor_relations": "https://investors.anaptysbio.com",
    "key_executives": [
        {
            "name": "G. Thomas Adams",
            "position": "CEO"
        },
        {
            "name": "Cynthia L. Breazeale",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Antibodies",
            "products": [
                "Etokimab",
                "ANB019",
                "ANB030"
            ]
        }
    ],
    "seo": {
        "meta_title": "AnaptysBio, Inc. | Innovative Monoclonal Antibodies",
        "meta_description": "Explore AnaptysBio, Inc., a leader in the development of therapeutic monoclonal antibodies aimed at treating severe diseases. Learn about their innovative pipeline and commitment to improving patient health.",
        "keywords": [
            "AnaptysBio",
            "Biotechnology",
            "Monoclonal Antibodies",
            "Therapeutics",
            "Immunology",
            "Oncology"
        ]
    },
    "faq": [
        {
            "question": "What does AnaptysBio specialize in?",
            "answer": "AnaptysBio specializes in the discovery and development of therapeutic monoclonal antibodies."
        },
        {
            "question": "Who is the CEO of AnaptysBio?",
            "answer": "G. Thomas Adams is the CEO of AnaptysBio, Inc."
        },
        {
            "question": "Where is AnaptysBio headquartered?",
            "answer": "AnaptysBio is headquartered in San Diego, California, USA."
        },
        {
            "question": "What are some of AnaptysBio's key products?",
            "answer": "Some key products include Etokimab, ANB019, and ANB030."
        },
        {
            "question": "When was AnaptysBio founded?",
            "answer": "AnaptysBio was founded in 2005."
        }
    ],
    "competitors": [
        "AMGN",
        "VRTX",
        "REGN",
        "BMY"
    ],
    "related_stocks": [
        "GILD",
        "MRNA",
        "ABBV",
        "JNJ"
    ]
}